Federal Circuit Court rules on patent litigation involving Prandin® (repaglinide)
2013-06-18 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark & Plainsboro, NJ 18 June 2013 - Today, the U.S. Court of Appeals for the Federal Circuit partially affirmed a 2011 District Court decision, with a 2-1 ruling that a claim in a Novo Nordisk patent related to the use of repaglinide in combination with metformin for the treatment of type 2 diabetes was invalid. This decision favors approval and launch of a generic repaglinide product. Further information Media: Mike Rulis +45 3079 3573 [email protected] Ken Inchausti (US) +1 609 240 2919 [email protected] Investors: Kasper Roseeuw Poulsen +45 4442 4303 [email protected] Frank Daniel Mersebach +45 4442 0604 [email protected] Lars Borup Jacobsen +45 3075 3479 [email protected] Jannick Lindegaard (US) +1 609 786 4575 [email protected] Company announcement No 45 / 2013
The release as fetched from its publisher. novonordisk.com ↗